Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial

Por Hart, C., Vogelhuber, M., Hafner, C., Landthaler, M., Berneburg, M., Haferkamp, S., Herr, W., Reichle, A.
Publicado no J Eur Acad Dermatol Venereol (2015)

Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial

Por Walter, I., Schulz, U., Vogelhuber, M., Wiedmann, K., Endlicher, E., Klebl, F., Andreesen, R., Herr, W., Ghibelli, L., Hackl, C., Wiest, R., Reichle, A.
Publicado no Med Oncol (2017)

Complexity of PEComas: Diagnostic approach, molecular background, clinical management

Por Utpatel, K., Calvisi, D. F., Köhler, G., Kühnel, T., Niesel, A., Verloh, N., Vogelhuber, M., Neu, R., Hosten, N., Schildhaus, H.-U., Dietmaier, W., Evert, M.
Publicado no Pathologe (2019)

Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Tr...

Por Vogelhuber, M., Feyerabend, S., Stenzl, A., Suedhoff, T., Schulze, M., Huebner, J., Oberneder, R., Wieland, W., Mueller, S., Eichhorn, F., Heinzer, H., Schmidt, K., Baier, M., Ruebel, A., Birkholz, K., Bakhshandeh-Bath, A., Andreesen, R., Herr, W., Reichle, A.
Publicado no Cancer Microenviron (2015)

Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

Por Vogelhuber, M., Feyerabend, S., Stenzl, A., Suedhoff, T., Schulze, M., Huebner, J., Oberneder, R., Wieland, W., Mueller, S., Eichhorn, F., Heinzer, H., Schmidt, K., Baier, M., Ruebel, A., Birkholz, K., Bakhshandeh-Bath, A., Andreesen, R., Herr, W., Reichle, A.
Publicado no Cancer Microenviron (2014)